September 19, 2025Frontiers in ImmunologyOpen Access

Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This network meta-analysis compares IL-17, IL-12/23, and IL-23 inhibitors' efficacy and safety profiles in psoriatic arthritis.

This analysis shows that IL-17 inhibitors exhibit superior efficacy for psoriatic arthritis over 12-24 weeks.
In the analysis of 22 RCTs with 9,241 patients, bimekizumab, secukinumab, and ixekizumab were top performers.
Using a network meta-analysis approach, efficacy and safety were evaluated through odds ratios and confidence intervals.
Results indicate that while IL-17 inhibitors are effective, bimekizumab has a less favorable safety profile than its counterparts.

Gao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 19, 2025Frontiers in ImmunologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

This network meta-analysis compares IL-17, IL-12/23, and IL-23 inhibitors' efficacy and safety profiles in psoriatic arthritis.

This analysis shows that IL-17 inhibitors exhibit superior efficacy for psoriatic arthritis over 12-24 weeks.
In the analysis of 22 RCTs with 9,241 patients, bimekizumab, secukinumab, and ixekizumab were top performers.
Using a network meta-analysis approach, efficacy and safety were evaluated through odds ratios and confidence intervals.
Results indicate that while IL-17 inhibitors are effective, bimekizumab has a less favorable safety profile than its counterparts.

Gao et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark